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Backgrounds: The number and activity of circulating endothelial progenitor cells (EPCs) in prehypertension is
preserved in premenopausal women. However, whether this favorable effect still exists in prehypertensive premenopausal
women with diabetes is not clear.
Methods: This study compared the number and functional activity of circulating EPCs in normotensive or
prehypertensive premenopausal women without diabetes mellitus and normotensive or prehypertensive
premenopausal women with diabetes mellitus, evaluated the vascular endothelial function in each groups,
and investigated the possible underlying mechanism.
Results: We found that compared with normotensive premenopausal women, the number and function of
circulating EPCs, as well as endothelial function evaluated by flow-mediated dilatation (FMD) in prehypertensive
premenopausal women were preserved. In parallel, the Tie2/Akt/eNOS signaling pathway and the plasma NO level or
NO secretion of circulating EPCs in prehypertensive premenopausal women was also retained. However, in presence
of normotension or prehypertension with diabetes mellitus, the number or function of circulating EPCs and FMD in
premenopausal women decreased. Similarly, the phosphorylation of Tie2/Akt/eNOS signaling pathway and the plasma
NO level or NO secretion of circulating EPCs was reduced in prehypertension premenopausal with diabetes mellitus.
Conclusion: The present findings firstly demonstrate that the unfavorable effects of diabetes mellitus on number and
activity of circulating EPCs in prehypertension premenopausal women, which is at least partially related to the
abnormal phosphorylation of Tie2/Akt/eNOS signaling pathway and subsequently reduced nitric oxide bioavailability. The
Tie2/Akt/eNOS signaling pathway may be a potential target of vascular protection in prehypertensive premenopausal
women with diabetes mellitus.
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Prehypertension is an intermediate state between nor-
motension and hypertension, which is associated with
increased cardiovascular risks [1–6]. Endothelial dys-
function, accompanied by prehypertension, plays a cru-
cial role in initiation and progression of atherosclerotic
vascular disease and subsequent clinical consequences
[7–9]. Increasing evidence suggests that circulating
endothelial progenitor cells (EPCs) are thought to be a
subset of cells derived from the bone marrow that plays
a pivotal role in accelerating reendothelialization, repair-
ing endothelial injury and improving endothelial func-
tion [10–13]. However, in presence of risk factors for
cardiovascular disease such as prehypertension, obesity
and smoke, the number and activity of circulating EPC
decreased, which may contribute to the development of
endothelial injury [14–16].
It is well known that diabetes mellitus (DM) is a com-
plex metabolic disorder characterized by increased mor-
bidity and mortality rates. Compared with nondiabetic
controls, patients with DM have a high risk of develop-
ing cardiovascular complications [17, 18], which corre-
lated with endothelial injury and dysfunction [19–22]. In
presence of diabetes, the number and activity of circulat-
ing EPCs, as well as flow-mediated dilatation (FMD)
were impaired [23–25]. Meanwhile, the number and ac-
tivity of circulating EPCs is related to endothelial func-
tion as evaluated by measurement of FMD [26, 27].
These results implies that the attenuated endothelial re-
pair capacity may be lead to diabetes-related vascular
injury.
It has proved that the occurrence of cardiovascular
risk is lower in premenopausal women than postmeno-
pausal women and age-matched men [28, 29]. The in-
creased cardiovascular diseases risks in postmenopausal
women may be partly associated with endothelial injury
and dysfunction [30]. Our previous studies showed that
the number and activity of circulating EPCs in prehyper-
tensive premenopausal women were preserved, indicat-
ing the retained endothelial repair capacity may
contribute to vascular protection concomitant with pre-
hypertensive premenopausal women [31]. However,
whether the beneficial effect still exists in prehyperten-
sive premenopausal women with diabetes is still unclear.
According to the previous studies revealing the unfavor-
able effect of DM on circulating EPCs [23–25], we hy-
pothesized that the number and activity of circulating
EPCs might be impaired in premenopausal prehyperten-
sive women with diabetes. In addition, nitric oxide (NO),
vascular endothelial growth factors (VEGF), and gran-
ulocyte macrophage colony- stimulating factor (GM-
CSF) regulate the number and function of circulating
EPCs [32–35]. EPC-mediated endothelial repair capacity
is associated with NO secretion by EPCs [36]. Tie2/PI3K/Akt signaling pathway is one major upstream ef-
fectors of eNOS. Our study and other investigations in-
dicated that the Tie2/Akt/eNOS signaling play an
important role in regulating the function of circulating
EPCs [37–40]. Based on the prior reports, we further as-
sumed that the changes of EPCs in the three groups
might be related to the alteration of NO, VEGF, GM-
CSF level in plasma or secretion by circulating EPCs,
and downregulation of Tie2/Akt/eNOS signaling path-
way in circulating EPCs might be also responsible for
decreased EPCs functional activity in premenopausal
prehypertensive women with diabetes. Hence, we ob-
served normotensive or prehypertensive premenopausal
women without diabetes mellitus and normotensive or
prehypertensive premenopausal women with diabetes
mellitus, evaluated the levels of NO、 VEGF and GM-
CSF in plasma or culture medium, and investigated the
expression of tie2/Akt/eNOS signaling pathway in each
groups. This study may provide useful information on
our understanding of the novel mechanism underlying
the alteration of endothelial repair capacity in prehyper-
tensive premenopausal women with diabetes mellitus.
Methods
Characteristics of subjects
Twenty normotensive premenopausal women, twenty pre-
hypertensive premenopausal women, twenty normotensive
premenopausal women with type 2 diabetes mellitus, and
20 prehypertensive premenopausal women with type 2
diabetes mellitus were studied. The enrolled subjects had
no known cardiovascular disease or ongoing drug treat-
ments (such as antiplatelet, anti-inflammatory or hypolip-
idemic agents). The normotensive premenopausal women
had no cardiovascular risk factors, a systolic blood pres-
sure < 120 mmHg, and a diastolic blood pressure
<80 mmHg. The prehypertensive women were diagnosed
as systolic blood pressure between 120 and 139 mmHg or
diastolic blood pressure between 80 and 89 mmHg ac-
cording to the Eight Joint National Committee (JNC 8)
guidelines [41]. Prehypertensive women with type 2 dia-
betes mellitus was newly diagnosed without any drug
treatments according to the guidelines in the Expert Com-
mittee Report of the American Diabetes Association [42].
The subjects with smokers, malignant disease, infection,
or inflammatory disorders were excluded as all these con-
ditions may influence the number or activity of EPC. The
subjects with breastfeeding or pregnant women and those
with previous hysterectomy or irregular menstrual cycles
were also excluded. The protocol of this study was ap-
proved by the Ethics Committee of the sixth affiliated hos-
pital of Sun Yat-Sen University, and written informed
consent for participation in the study was obtained from
participants. The main characteristics of the study popula-
tion are shown in Table 1.
Table 1 Clinical and biochemical characteristics




(n = 20) (n = 20) (n = 20) (n = 20)
Age (years) 42.7 ± 5.8 44.9 ± 4.0 45.2 ± 6.6 45.4 ± 5.1
Height (cm) 162.3 ± 5.7 160.5 ± 5.9 161.9 ± 6.1 161.1 ± 5.2
Weight (Kg) 58.7 ± 5.7 59.5 ± 5.7 62.1 ± 4.8 64.1 ± 4.4
BMI (kg/cm2) 23.5 ± 2.7 22.9 ± 2.1 24.0 ± 2.1 23.8 ± 1.5
Systolic blood pressure (mmHg) 108.8 ± 6.5 130.4 ± 5.5a 111.0 ± 6.0 131.3 ± 4.9a
Diastolic blood pressure (mmHg) 68.5 ± 5.0 80.3 ± 4.4a 70.9 ± 4.8 80.9 ± 5.4a
Heart rate (beats/min) 72.2 ± 7.9 72.8 ± 7.4 73.7 ± 10.2 75.0 ± 7.7
AST (mmol/L) 24.3 ± 5.8 26.9 ± 8.1 27.7 ± 6.0 25.7 ± 6.5
ALT (mmol/L) 22.9 ± 5.2 24.5 ± 5.1 24.8 ± 6.1 21.7 ± 5.7
BUN (mmol/L) 5.7 ± 0.8 5.5 ± 1.2 5.9 ± 1.3 5.4 ± 1.1
Cr (mmol/L) 72.2 ± 14.8 66.4 ± 16.4 73.1 ± 15.2 65.2 ± 18.0
LDL (mmol/L) 2.98 ± 0.33 2.88 ± 0.55 3.10 ± 0.37 3.09 ± 0.36
TC (mmol/L) 4.93 ± 0.44 4.92 ± 0.65 5.11 ± 0.39 5.08 ± 0.42
HDL (mmol/L) 1.37 ± 0.24 1.40 ± 0.21 1.31 ± 0.19 1.34 ± 0.16
TG (mmol/L) 1.44 ± 0.19 1.39 ± 0.17 1.50 ± 0.21 1.46 ± 0.12
FPG (mmol/L) 4.71 ± 0.67 4.51 ± 0.61 8.91 ± 1.16b 8.73 ± 1.08b
2hPG(mmol/L) 6.25 ± 0.66 6.17 ± 0.67 10.87 ± 1.72b 10.31 ± 1.61b
HbA1C(%) 5.31 ± 0.58 5.18 ± 0.63 8.49 ± 1.47
b 8.15 ± 1.52b
hrCRP (mmol/L) 0.961 ± 0.509 1.130 ± 0.615 1.953 ± 0.852b 1.828 ± 0.882b
FMD(%) 10.29 ± 1.16 9.79 ± 1.22 5.87 ± 5.49b 5.49 ± 0.129b
GMD(%) 22.49 ± 2.12 21.89 ± 2.45 21.05 ± 2.47 21.37 ± 2.68
Abbreviation: BMI body mass index, LDL low-density lipoprotein, TC total cholesterol, HDL high density lipoprotein, TG triglyeride, FPG fasting plasma glucose, 2hPG
2-h plasma glucose, HbA1C glycosylated hemoglobin, hrCRP hyper-sensitive C-reactive protein, GMD glyceryl trinitrate-mediated dilation, FMD flow-mediated
brachial artery dilatation
Notes: Data are given as mean ± SD. avs normotension; bvs without DM
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isolation and routine blood and biochemistry tests in-
cluding serum total cholesterol, triglycerides, high-
density lipoprotein cholesterol, LDL-cholesterol, fasting
blood glucose (FBG) and high-sensitivity CRP were
taken from the three groups in the morning after over-
night fasting. All subjects received checks, menstrual pe-
riods of the menstrual cycle (day 2 to day 5 after the
first day of menstrual bleeding).
Evaluation of number of circulating EPCs by flow
cytometry analysis and cell culture assay
Detection of EPCs was performed as our previous studies
and other investigation described [40, 43]. The count of cir-
culating EPCs was evaluated by the ratio of CD34 +KDR+
cells per 100 peripheral blood mononuclear cells
(PBMNCs). The circulating EPCs were isolated, cultured
and quantified using DiI-acLDL uptake and FITC-labled
Ulex europeus agglutin (lectin) staining as our previous de-
scribed report [40]. The cultured EPC number was evalu-
ated by DiI-acLDL/lectin doublepositive cells/×200, andcounted manually by two independent observers blinded to
the study.
Migration and Proliferation assay of circulating EPCs
EPC migration and proliferation assay was determined
as our previous studies reported [40, 43]. EPCs were har-
vested by centrifugation, resuspended in 500 μl EBM,
and counted. Then, 2 × 104 EPCs were placed in the
upper chamber of a modified Boyden chamber. The
chamber was placed in a 24-well culture dish containing
EBM and human recombinant VEGF (50 ng/mL). After
incubation at 37 °C for 24 h, the lower side of the filter
was washed with PBS and fixed with 2 % paraformal-
deyde. For quantification, cell nuclei were stained with
DAPI. Cells migrating into the lower chamber were
counted manually in 3 random microscopic fields.
EPC proliferation was performed as following. After
being cultured for 7 days, EPCs were digested with
0.25 % trypsin and then cultured in serum-free medium
in 96-well culture plate (200 μL/well). After being cul-
tured for 24 h, EPCs were supplemen-ted with 10 μ l
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other 4 h. Then the supernatant was discarded by aspir-
ation and the EPC preparation was shaked with 200 μ L
dimethyl sulfoxide (DMSO) for 10 min, before the OD
value was measured at 490 nm.
Measurement of NO、VEGF and GM-CSF levels in plasma
and secretion by EPCs
Plasma was assayed for NO、VEGF and GM-CSF levels.
Nitrite, the stable metabolite of nitric oxide, was esti-
mated by using Greiss method as our previous studies
reported [32]. The formation of nitrite (NO2
−) and nitrate
(NO3
−) was detected in cell culture supernatants. This
assay determined the total NO based on the enzymatic
conversion of NO3
− to NO2
− by nitrate reductase (Sigma),
and detection of nitrite as an azo dye product of the
Greiss reaction. The results are presented as μmol NOx
of NO3ˉ/NO2
− per liter of medium. Plasma levels of
VEGF and GM-CSF were measured by high-sensitive
ELISA assays (R&D Systems, Wiesbaden, Germany) ac-
cording to our previous studies [32].
The cultured EPCs were switched to the DMEM/20 %-
fetal bovine serum (no supplemental growth factors) for
48 h. Then, the conditioned media were assayed for
NO、VEGF and GM-CSF as previously described [32].
Flow mediated dilatation
The measurement of FMD were performed according to
the previous reports [44, 45]. Brachial artery FMD was
measured by highresolution ultrasonography using a 5–
12 MHz linear transducer on an HDI 5000 system
(Washington, USA). The brachial artery was studied 20
to 100 mm proximal to the antecubital fossa in supine
participants after 15 min rest [44, 45]. Pressure in an
upper-forearm sphygmomanometer cuff was raised to
250 mmHg for 5 min and FMD calculated as the per-
centage increase in mean diastolic diameter after react-
ive hyperaemia 55 to 65 s after deflation to baseline [44,
45]. After a further 15 min, 400 μg sublingual glyceryl
trinitrate (GTN) was given and diastolic diameter
remeasured after 5 min for measurement of endothelial-
independent dilatation [44, 45].
Western blot analysis
EPC proteins were harvested by cell lysis buffer (Cell
SignalingTechnology Inc, Danvers, MA, USA). Protein
extracts were subjected to SDS-PAGE, transferred to
polyvinylidene fluoride membranes(Cell Signaling Tech-
nology Inc.). The following antibodies were used: rabbit
phospho-Tie2, Tie2, phospho-Akt, Akt, phospho-eNOS,
eNOS(1:1000; Cell Signaling Technology Inc.) andβ-
actin (1:1000; Santa Cruz Technology Inc.). Proteins
were visualized with HRP-conjugated anti-rabbit IgG
(1:2000; Cell Signaling Technology Inc.) or HRP-conjugated anti-mouse IgG (1:5000; Cell Signaling Tech-
nology Inc.), followed by use of the ECL chemilumines-
cence system (Cell Signaling Technology Inc.). The
intensity of immunoreactive bands was analyzed. The re-
sults were expressed as the ratio of specific phosphory-
lated proteins to total proteins for the phosphorylation
of Tie2, Akt, and eNOS in human EPCs, and the ratio of
total Tie2, Akt, and eNOS proteins to ß-actin for expres-
sion of Tie2, Akt, and eNOS in human EPCs. The statis-
tical comparisons for western blot analysis were made
relative to normotension.
Statistic analysis
The statistic software was SPSS V11.0 (SPSS Inc.,
Chicago, Illinois). All data were expressed as mean ± SD.
Comparisons between the four groups were analyzed by
two-factor analysis of variance (status of with or without
diabetes mellitus, status of normotension or prehyper-
tension). When indicated by a significant F-value, a post
hoc test using the Newman-Keuls method identified sig-
nificant differences among mean values. Comparisons in
Tie2/Akt/eNOS signaling pathway between the three
groups were analyzed by using the unpaired Student’s t
test and one-way ANOVA. Univariate correlations were
calculated using Pearson’s coefficient (r). P-values less
than 0.05 were considered statistical significance.
Results
Clinical characteristics
As shown in Table 1, the four groups were similar in
terms of age and BMI. There were no differences be-
tween the levels of triglycerides, cholesterol, LDL-
cholesterol, high-density lipoprotein cholesterol in the
three groups (P > 0.05). Compared with normotensive
premenopausal women with or without diabetes melli-
tus, the systolic and diastolic blood pressure in prehy-
pertensive premenopausal women with or without
diabetes mellitus was higher (P < 0.05). FBG, 2hPG,
HbA1C, FMD and hr-CRP in normotensive or prehyper-
tensive women with diabetes mellitus were significantly
higher than those in normotensive or prehypertensive
women without diabetes mellitus (P < 0.05). However,
there were no differences in FMD between normotensive
and prehypertensive women (P > 0.05). The GMD in the
four groups was similar (P > 0.05).
The number and function of circulating EPCs in the four
groups
As shown in Fig. 1a and b, there was no difference in
number of circulating EPCs evaluated by FACS analysis
or cell culture assay between normotensive and prehy-
pertensive premenopausal women (P > 0.05). However,
the number of circulating EPCs was significantly lower
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Fig. 1 The number and activity of circulating EPCs in the four groups. Evaluated by a FACS analysis or b cell culture assay, the number of circulating EPCs
in prehypertensive premenopausal women without diabetes mellitus was similar to that in normotensive premenopausal women without
diabetes mellitus, but higher than that in normotensive or prehypertensive women with diabetes mellitus. There was no difference in the
migratory c and proliferative d activities between normotensive and prehypertensive premenopausal women. The migratory c and proliferative d activities
of cultured EPCs was lower in normotensive or prehypertensive premenopausal women with diabetes mellitus than that in normotensive
or prehypertensive premenopausal women without diabetes mellitus. Data are given as mean ± SD (*vs normotension; # vs without DM,
n = 20 for each group)
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or prehypertensive premenopausal women without dia-
betes (P < 0.05). Figure 1c and d showed that the migra-
tory or proliferative function of EPCs in normotensive
premenopausal women was equal to that in prehyper-
tensive premenopausal women (P > 0.05). However, the
migratory or proliferative function of EPCs in normoten-
sive or prehypertensive premenopausal women with dia-
betes were lower than those in normotensive or
prehypertensive premenopausal women without diabetes
(P < 0.05). These results indicated that the preserved
number and activity of circulating EPCs in prehyperten-
sive premenopausal women was impaired in presence of
diabetes.
Plasma NO、VEGF and GM-CSF levels in the four groups
As shown in Fig. 2, the plasma NO levels in normo-
tensive premenopausal women was similar to that in
prehypertensive premenopausal women (P > 0.05).
However, the plasma NO levels in normotensive orprehypertensive premenopausal women with diabetes
were significantly lower than those in normotensive or
prehypertensive premenopausal women without dia-
betes (P < 0.05). Different from the plasma NO level,
there was no significant difference in the plasma VEGF
and GM-CSF level among the four groups (P > 0.05).NO、VEGF and GM-CSF secretion by EPCs in the four
groups
Figure 3 showed the NO、VEGF and GM-CSF secre-
tion by EPCs in the four groups. The NO secretion by
cultured EPCs in normotensive premenopausal
women without diabetes was almost equal to that in
prehypertensive premenopausal women without dia-
betes (P > 0.05), but higher than that in normotensive
or prehypertensive women with diabetes mellitus (P < 0.05).
However, no difference was shown among the four groups
in term of either VEGF or GM-CSF secretion by cultured
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Fig. 2 (See legend on next page.)
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Fig. 2 The plasma NO、VEGF and GM-CSF levels in the four groups. a The plasma NO level in normotensive premenopausal women without diabetes
mellitus was almost equal to that prehypertensive premenopausal women without diabetes mellitus. Compared with normotensive or prehypertensive
premenopausal women without diabetes mellitus, the plasma NO level in normotensive or prehypertensive women with diabetes mellitus decreased. No
significant difference was found in plasma VEGF b or GM-CSF c level among the four groups. Data are given as mean ± SD (*vs normotension; # vs without
DM, n= 20 for each group)
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FMD
Figure 4a and d showed that the correlation between
the number or function of circulating EPCs and FMD.
There was significant correlation between FMD and
the number of circulating EPCs evaluated by flow cy-
tometry analysis (r = 0.41, P < 0.05) or by cell culture
(r = 0.74, P < 0.05). Similarly, the EPC migration and
EPC proliferation significantly correlated with plasma
FMD (r = 0.64, P < 0.05, and r = 0.56, P < 0.05, respect-
ively). Figure 4e and f showed that the correlation be-
tween the plasma NO level and NO secretion by EPCs
and FMD. There was obvious correlation between
FMD and plasma NO level (r = 0.63, P < 0.05), and NO
secretion by EPCs (r = 0.62, P < 0.05).The Tie2/Akt/eNOS signaling pathway of circulating EPCs
in the three groups
To investigate the possible mechanism underlying the defi-
ciency in NO secretion by cultured EPCs in presence of
prehypertension with diabetes mellitus, we further evalu-
ated the expression of Tie2/Akt/eNOS signaling pathway of
circulating EPCs in the three groups. As shown in Fig. 5,
the phosphorylation of tie2, Akt and eNOS of circulating
EPCs in prehypertensive premenopausal women and
normotensive premenopausal women without diabetes ex-
hibited no significant difference (P > 0.05). However, the
phosphorylation of tie2, Akt, and eNOS of circulating EPCs
in prehypertensive and normotensive premenopausal
women without diabetes were higher than that in pre-
hypertensive premenopausal women with diabetes
mellitus (P < 0.05). In addition, there was no difference
in the expression of total tie2, Akt and eNOS of circu-
lating EPCs in the three groups (P > 0.05).Discussion
The present results indicates that in presence of diabetes
mellitus, the preserved endothelial function in prehyper-
tensive premenopausal women was attenuated, which
may be related to impaired number and function of cir-
culating EPCs. This alteration in circulating EPCs may
be due to decreased NO production, and the abnormal
phosphorylation of Tie2/Akt/eNOS signaling pathway
may be the underlying mechanism. Therefore, this study
firstly demonstrates the unfavorable effects of diabetes
mellitus on endothelial function and circulating EPCs inprehypertensive premenopausal women and its possible
underlying mechanism.
Diabetes mellitus is a major risk factor for the develop-
ment of cardiovascular disease and is associated with a
high cardiovascular morbidity and mortality [17, 18]. It
is generally accepted that the number and function ac-
tivity of circulating EPCs is impaired in diabetes patients
[23–25], supporting the role of suppressed endothelial
repair capacity in pathogenesis of diabetes-related vascu-
lar abnormalities. Our previous studies show that in pre-
hypertension premenopausal women the number and
activity of circulating EPCs were preserved [31], indicat-
ing that EPC-mediated vascular protection in prehyper-
tension premenopausal women may due to increased
endothelial repair capacity. However, the effect of dia-
betes on number and activity of circulating EPCs in pre-
hypertension premenopausal women is unclear. In this
investigation, we found that in presence of diabetes mel-
litus, both the number and functional activity of circulat-
ing EPCs is impaired in prehypertensive premenopausal
women. FMD is regarded as a reliable and reproducible
technique for assessment of endothelial dysfunction in
cardiovascular disease [44–46]. Our results also revealed
that FMD was reduced in prehypertensive premeno-
pausal women in presence of diabetes mellitus and there
is a significant correlation between the number or func-
tion activity of circulating EPCs and FMD, indicating
that the attenuated endothelial repair capacity may lead
to endothelial dysfunction in prehypertensive premeno-
pausal women with diabetes mellitus.
NO、VEGF and GM-CSF are the pivotal factors to
regulate the number and function of circulating EPCs
[32–35]. Previous studies demonstrated that diabetes
mellitus impairs eNOS activity, resulting in decreased
NO bioavailability [47]. Accordingly, we assumed that
the effect of diabetes mellitus on number and activity of
circulating EPCs in prehypertension premenopausal
women might be associated with NO、VEGF and GM-
CSF. In result, we found that compared with normoten-
sive premenopausal women, the plasma NO level or NO
secretion by EPCs was restored in prehypertension
premenopausal women, but reduced in prehypertensive
premenopausal women with diabetes mellitus. The
present results indicates that diabetes-related decreased
number and activity of circulating EPCs in prehyperten-
sion premenopausal women may be related to the re-



































without DM DM 






















Fig. 3 (See legend on next page.)
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Fig. 3 The NO、VEGF and GM-CSF secretion by EPCs in the four groups. a The NO secretion by EPCs was the same in normotensive premenopausal
women without diabetes mellitus as that in prehypertensive premenopausal women without diabetes mellitus, but higher than that in normotensive or
prehypertensive women with diabetes mellitus. There was no difference in VEGF b or GM-CSF c secretion by EPCs among the four groups. Data are given
as mean ± SD (*vs normotension; # vs without DM, n= 20 for each group)
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was found among the three groups, suggesting that the
alteration of endothelial repair capacity in prehyperten-
sive premenopausal women with diabetes mellitus may
be independent of the changes in plasma VEGF or GM-
CSF level or secretion by cultured EPCs. In addition, we
also found that there was a positive correlation between
the plasma NO level or NO secretion by EPCs and
FMD, further supporting that both reduced systemic NO
production and endogenous NO biosynthase by circulat-
ing EPCs may contribute to endothelial dysfunction in
prehypertensive premenopausal women with diabetes
mellitus.
Tie2/Akt/eNOS pathway plays an important role in
regulating the number and function of circulating EPCs
and subsequently accelerating endothelial repair capacity
for vascular injury [48–51]. In this investigation, we
found that when compared with normotensive premeno-
pausal women, the phosphorylation of tie2, Akt, and
eNOS of circulating EPCs were preserved in prehyper-
tensive premenopausal women without diabetes, but re-
duced in prehypertensive premenopausal women with
diabetes mellitus. However, the expression of tie2, Akt
and eNOS of circulating EPCs showed no difference in




































































Fig. 4 The correlation between circulating EPCs or NO level and FMD. a an
circulating EPCs and FMD. The number of circulating EPCs evaluated by FA
a correlation between the EPC proliferatory c or migratory d and FMD. e a
NO secretion by EPCs and FMD. There was a correlation between the plasmdecreased phosphorylation of tie2, Akt, and eNOS but
not the alteration of expression of Tie2/Akt/eNOS path-
way contributes to reduced NO secretion by circulating
EPCs in prehypertensive premenopausal women with
diabetes mellitus. Interestingly, the phosphorylation of
eNOS was slightly lower than the phosphorylation of
tie2 and Akt of circulating EPCs in prehypertensive pre-
menopausal women with diabetes mellitus, implying that
other mechanism may be involved in abnormal activity
of eNOS of circulating EPCs. Previous study reported
that in circulating EPCs in presence of type 2 diabetes,
GTPCH Ι deactivation leads to BH4 efficiency and sub-
sequent eNOS uncoupling [52]. Thus, we inferred that
GTPCH Ι deactivation may be another mechanism
underlying the decreased phosphorylation of eNOS of
circulating EPCs in prehypertensive premenopausal
women with diabetes mellitus.
The present study has some implications as follows.
First, different from prehypertensive premenopausal
women without diabetes mellitus, the endothelial func-
tion together with number or activity of circulating EPCs
in prehypertensive premenopausal women with diabetes
mellitus were impaired, indicating that the intervention
to improve endothelial function and vascular repair








































d d showed that the correlation between the number or activity of
CS a or by cell culture b strongly correlated with the FMD. There was
nd f showed that the correlation between the plasma NO level and













































































































































































Fig. 5 The Tie2/Akt/eNOS signaling pathway of circulating EPCs in the three groups. There was no difference in the phosphorylation of tie2 a,
Akt b and eNOS c of circulating EPCs between prehypertensive and normotensive premenopausal women without diabetes mellitus. The
phosphorylation of tie2 a, Akt b and eNOS c of circulating EPCs in prehypertensive and normotensive premenopausal women without diabetes
mellitus exceeded that in prehypertensive premenopausal women with diabetes. The expression of tie2 a, Akt b and eNOS c of circulating EPCs
in the three groups exhibited no difference. Data are given as mean ± SD. (*P < 0.05 compared with normotension without diabetes mellitus,
#P < 0.05 compared with prehypertension without diabetes mellitus, n = 20 for each group)
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our results show that diabetes mellitus impaired the
number or function of circulating EPCs and subse-
quently reduced NO production in prehypertensive pre-
menopausal women, which is at least in part mediated
by tie2/Akt/eNOS signaling pathway. The date reported
here proved that in presence of prehypertension with
diabetes mellitus, the tie2/Akt/eNOS signaling pathway
in circulating EPCs may be useful for therapeutic ap-
proach of endothelial repair capacity.
Conclusions
The present study for the first time demonstrates the
unfavorable effects of diabetes on number and activity of
circulating EPCs and endothelial function in prehyper-
tensive premenopausal women, which is associated with
decreased NO production and abnormal phosphoryl-
ation of Tie2/Akt/eNOS signaling pathway. The attenu-
ated endogenous endothelial repair capacity may be the
important mechanism underlying vascular injury in pre-
hypertensive premenopausal women with diabetes. Our
findings provide new insight into vascular protection in
patients of prehypertensive premenopausal women with
diabetes mellitus, suggesting that Tie2/Akt/eNOS signal-
ing pathway may be a potential target for enhancing en-
dogenous endothelial repair capacity.Abbreviations
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